381
Participants
Start Date
April 16, 2019
Primary Completion Date
April 8, 2027
Study Completion Date
April 8, 2027
bb2121
bb2121
Daratumumab
Daratumumab
Pomalidomide
Pomalidomide
Dexamethasone
Dexamethasone
Bortezomib
Bortezomib
Ixazomib
Ixazomib
Lenalidomide
Lenalidomide
Carfilzomib
Carfilzomib
Elotuzumab
Elotuzumab
Local Institution - 202, Leuven
Local Institution - 251, Bern
Local Institution - 109, Birmingham
Local Institution - 119, New York
Local Institution - 115, New York
Local Institution - 135, New York
University of Pittsburgh Medical Center William M. Cooper Ambulatory Care Pavillion, Pittsburgh
Local Institution - 111, Philadelphia
Local Institution - 110, Philadelphia
Local Institution - 514, Hamburg
Local Institution - 113, Durham
Local Institution - 131, Atlanta
Local Institution - 140, Atlanta
Local Institution - 750, Pamplona
Local Institution - 401, Toulouse
Local Institution - 108, Jacksonville
Local Institution - 102, Tampa
Local Institution - 751, Salamanca
Local Institution - 106, Nashville
Local Institution - 611, Bologna
Local Institution - 513, Düsseldorf
Local Institution - 403, Nantes
Local Institution - 515, Cologne
Local Institution - 107, Madison
Local Institution - 402, Lille
Local Institution - 139, Chicago
Local Institution - 114, St Louis
Local Institution - 512, Heidelberg
Local Institution - 400, Paris
Local Institution - 118, Dallas
Local Institution - 103, Dallas
Local Institution - 132, Houston
Local Institution - 142, Aurora
Local Institution - 136, Salt Lake City
Local Institution - 141, Scottsdale
Local Institution - 145, Los Angeles
Local Institution - 122, Los Angeles
Local Institution - 124, Palo Alto
Local Institution - 511, Würzburg
Local Institution - 105, Seattle
Local Institution - 100, Indianapolis
Local Institution - 112, Westwood
Local Institution - 104, Baltimore
Local Institution - 134, Boston
Local Institution - 123, Boston
University Of Michigan Comprehensive Cancer Center, Ann Arbor
Local Institution - 125, Rochester
Local Institution - 138, Hackensack
Local Institution - 302, Calgary
Local Institution - 303, Toronto
Local Institution - 806, Bunkyō City
Local Institution - 804, Isehara City, Kanagawa
Local Institution - 807, Nagoya
Local Institution - 805, Shibuya-ku
Local Institution - 650, Amsterdam
Local Institution - 651, Rotterdam
Local Institution - 700, Oslo
Local Institution - 800, Stockholm
Local Institution - 850, Leeds
Local Institution - 851, London
Lead Sponsor
Celgene
INDUSTRY